IDH1 and central nervous system cancer: A subset of leukemia cells with mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2), and IDH1-mutant glioma cells have been shown to be particularly sensitive to glutaminase inhibition [10].